CRNX News and Press, Crinetics Pharmaceuticals Inc.

SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET that day to...

SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 137,900 shares of its com...

2024-07-09 07:00:00 ET Summary Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation...

2024-06-25 22:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-21 17:40:12 ET Read the full article on Seeking Alpha For further details see: Crinetics Pharmaceuticals files for mixed shelf, to sell shares for holders

SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Ernst & Young LLP (EY US) today announced that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, was named an Entrepreneur Of The Year ® 2024 Pacific Southwest Award winner. Entrepreneur Of The Year is the preeminen...

SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 158,000 shares of its com...

2024-06-04 09:55:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-04 09:15:06 ET Oppenheimer analyst issues OUTPERFORM recommendation for CRNX on June 4, 2024 07:27AM ET. The previous analyst recommendation was Outperform. CRNX was trading at $46.28 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-06-04 09:00:05 ET Leland Gershell from Oppenheimer issued a price target of $74.00 for CRNX on 2024-06-04 07:27:00. The adjusted price target was set to $74.00. At the time of the announcement, CRNX was trading at $46.28. The overall price target consensus is at $67...